Trial Profile
A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms SINE
- 01 May 2023 Results (N=30)assessing efficacy and safety of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, published in the European Journal of Haematology.
- 02 Mar 2023 Planned End Date changed from 25 Dec 2022 to 25 Dec 2024.
- 02 Mar 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2024.